文献速递胸部肿瘤

洛拉替尼治疗ALK阳性非小细胞肺癌关键2期研究的最终总生存与长期安全性:简要报告

Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report.
PubMed 文献 · J Thorac Oncol · 2024-11-22

该关键2期研究最终分析纳入接受洛拉替尼100 mg每日一次治疗的ALK阳性晚期非小细胞肺癌患者,各扩展队列中位总生存从19.2个月至未达到不等;至少随访5年后证实洛拉替尼在初治和经治患者中具有显著活性、延长总生存且安全性总体一致。

要点

  • 初治队列EXP1中位OS未达到(95%CI:NR-NR)。
  • ≥2种ALK TKI经治的EXP4-5中位OS为19.2个月(95%CI:15.4-30.2)。
  • 因不良事件永久停药35例(13%),剂量降低77例(28%)。

核心结论

  • 至少随访5年后,该全球2期研究最终分析证实洛拉替尼在初治和经治ALK阳性NSCLC患者中具有显著活性、延长总生存,安全性结果总体一致。

研究设计与样本

  • 关键2期研究纳入ALK阳性晚期NSCLC成人患者,按既往治疗分为扩展队列EXP1-5,接受洛拉替尼100 mg口服每日一次,连续21天为一周期。
  • EXP1为初治患者30例,EXP2-3A为克唑替尼±化疗后进展59例,EXP3B为一种第二代ALK TKI±化疗后进展28例,EXP4-5为≥2种ALK TKI±化疗后进展111例,EXP3B-5为≥1种ALK TKI±化疗后进展139例。
  • 主要终点为客观缓解率,次要终点包括总生存和安全性。

主要发现

  • 中位OS:EXP1未达到(95%CI:NR-NR),EXP2-3A未达到(95%CI:51.5-NR),EXP3B为37.4个月(95%CI:12.3-NR),EXP4-5为19.2个月(95%CI:15.4-30.2),EXP3B-5为20.7个月(95%CI:16.1-30.3)。
  • 导致剂量降低的全因不良事件报告于77例患者(28%),导致暂时停药158例(57%),导致永久停药35例(13%)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance mutations. We present the overall survival (OS) and long-term safety of lorlatinib in patients with advanced ALK-positive NSCLC from the final analyses of the pivotal phase 2 study. METHODS: Adults with ALK-positive NSCLC, enrolled in expansion cohorts (EXPs) on the basis of prior therapy (EXP1-5), received lorlatinib 100 mg orally once daily in continuous 21-day cycles. The primary endpoint was the objective response rate; secondary endpoints included OS and safety. RESULTS: Thirty patients were enrolled in EXP1 (treatment naïve), 59 in EXP2-3A (disease progression after crizotinib ± chemotherapy), 28 in EXP3B (disease progression after one second-generation ALK tyrosine kinase inhibitor [TKI] ± chemotherapy), 111 in EXP4-5 (disease progression after ≥2 ALK TKIs ± chemotherapy), and 139 in EXP3B-5 (disease progression after ≥1 ALK TKI ± chemotherapy). Median OS was not reached (NR) (95% confidence interval [CI]: NR-NR) in EXP1, NR (95% CI: 51.5-NR) in EXP2-3A, 37.4 months (95% CI: 12.3-NR) in EXP3B, 19.2 months (95% CI: 15.4-30.2) in EXP4-5, and 20.7 months (95% CI: 16.1-30.3) in EXP3B-5. All-cause adverse events leading to dose reduction were reported in 77 patients (28%), temporary treatment discontinuation in 158 patients (57%), and permanent discontinuation in 35 patients (13%). CONCLUSIONS: After a minimum follow-up of five years, final analyses from the global phase 2 study confirmed substantial activity, prolonged OS, and generally consistent safety findings with lorlatinib in treatment-naïve and previously treated patients with ALK-positive NSCLC. CLINICALTRIALS: gov NCT01970865.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ou SI, Solomon BJ, Besse B, et al. Final Overall Survival and Long-Term Safety of Lorlatinib in Patients With ALK-Positive NSCLC From the Pivotal Phase 2 Study: A Brief Report. J Thorac Oncol. 2024. PMID: 39581380. doi:10.1016/j.jtho.2024.11.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。